White House Pharma Import Tariffs Reshape US Sector: Domestic Producers Eli Lilly and Amgen Gain as Pfizer, Merck Face Headwinds
On April 11, 2026, CNBC highlighted how Trump administration regulatory policies combined with China's exploding biotech sector are rapidly eroding Europe's long-standing dominance in global pharmaceuticals. This shift sets the stage for proposed White House tariffs on imported drugs, primarily targeting manufacturing hubs in Europe and Asia, to bolster US production and shield domestic revenues. Investors should eye which US pharma leaders—those with heavy US manufacturing footprints—stand to gain market share and margins, versus those entangled in vulnerable global supply chains.
Europe has historically supplied up to 30% of active pharmaceutical ingredients (APIs) and finished drugs to the US market, per industry estimates. Trump's tariff agenda, echoing his first-term trade wars, aims to repatriate production amid geopolitical tensions and China's biotech investments surpassing $50 billion annually. Recent earnings calls underscore the divide: Eli Lilly and Amgen tout massive US manufacturing expansions, while Pfizer and Merck grapple with international exposure and generic pressures. With tariffs potentially adding 10-25% to import costs, domestic-focused players could see EPS uplift of 5-10%, while others face margin erosion.
Eli Lilly: US Manufacturing Ramp Shields Against Tariffs
Eli Lilly (LLY) is primed to thrive under import tariffs, having aggressively expanded US capacity to meet surging demand for GLP-1 drugs like Mounjaro and Zepbound. In its Q4 2025 earnings, management announced new US facilities in North Chicago and Puerto Rico, producing 1.6x more incretin doses in H1 2025 alone. This insulates LLY from European API reliance, where competitors source 20-30% of inputs.
| Metric | FY2025 Value |
|---|---|
| Revenue | $65.2B (+45% YoY) |
| Gross Margin | 83.8% |
| EBITDA Margin | 42.9% |
| Net Income | $20.6B |
| Market Cap | $888B |
| P/E TTM | 40.8 |
| 1M Return | -4.6% |
LLY's revenue exploded on obesity drug demand, with 2026 guidance at $80-83B (25% growth). Tariffs would widen its moat, pricing out imported rivals. Verdict: Strong buy—best-positioned winner.
Amgen: Biosimilars and US Investments Drive Tariff Resilience
Amgen (AMGN) benefits from $40B+ in US manufacturing and R&D since 2017, including Ohio and North Carolina expansions. Its biosimilars like WEZLANA and AMJEVITA target imported blockbusters, gaining share as tariffs hike foreign costs. Q4 2025 highlights included 14 blockbusters with double-digit growth and Phase III wins in obesity (MariTide).
| Metric | FY2025 Value |
|---|---|
| Revenue | $36.7B (+10% YoY) |
| Gross Margin | 70.8% |
| EBITDA Margin | 43.1% |
| Net Income | $7.7B |
| Market Cap | $189B |
| EV/EBITDA | 12.6 |
| 3M Return | +12.3% |
2026 revenue guidance: $37-38.4B. Domestic focus minimizes tariff pain, boosting ROE to ~89%. Verdict: Buy—undervalued tariff tailwind.
AbbVie: Immunology Growth and US Capex Offset Global Ties
AbbVie (ABBV) mixes US strength with some European exposure but counters via $10B+ US investments over the next decade. Skyrizi and Rinvoq drove 40%+ immunology growth in 2025, with new sites in North Chicago. Q4 call emphasized 90 clinical programs and acquisitions like Capstan for in vivo CAR-T.
| Metric | FY2025 Value |
|---|---|
| Revenue | $61.2B (+9% YoY) |
| Gross Margin | 83.7% |
| EBITDA Margin | 46.3% |
| Net Income | $4.2B |
| Market Cap | $368B |
| EV/EBITDA | 15.3 |
| 1M Return | -4.9% |
2026 net revenues ~$67B (9.5% growth). Tariffs aid aesthetics and oncology vs. imports. Verdict: Hold—solid but less pure-play.
Johnson & Johnson: Diversified but Vulnerable Overseas
J&J (JNJ) spans pharma and medtech, with Innovative Medicine at $15B+ quarterly sales. However, global supply chains expose it to tariffs, especially in Europe-sourced APIs for Darzalex and Stelara biosimilars. Q4 2025 noted 5.4% operational growth but flagged orthopedics separation.
| Metric | FY2025 Value |
|---|---|
| Revenue | $94.2B (+6% YoY) |
| Gross Margin | 72.8% |
| EBITDA Margin | 42.4% |
| Net Income | $26.8B |
| Market Cap | $575B |
| P/E TTM | 21.5 |
| 3M Return | +15.6% |
2026 sales midpoint $100B (6.2% growth). Tariffs could squeeze margins by 1-2%. Verdict: Neutral—scale buffers but exposure lingers.
Pfizer: Global Chains Spell Margin Trouble
Pfizer (PFE) relies heavily on international manufacturing, including Europe for Prevnar and Eliquis precursors. Post-COVID revenue normalization (FY2025: $62.6B, -2% YoY) leaves it vulnerable; Q4 call cited Seagen integration but generics/LOE at $1.5B drag. Tariffs exacerbate cost pressures.
| Metric | FY2025 Value |
|---|---|
| Revenue | $62.6B (-2% YoY) |
| Gross Margin | 70.3% |
| EBITDA Margin | 24.1% |
| Net Income | $7.8B |
| Market Cap | $153B |
| P/E TTM | 19.7 |
| 1M Return | -2.8% |
2026 revenues $59.5-62.5B. Verdict: Sell—prime tariff loser.
Merck: Oncology Reliance Hits Tariff Wall
Merck (MRK) sources Keytruda APIs partly from Europe, with Verona Pharma acquisition adding COPD exposure. FY2025 revenue $65B (+1% YoY) but Q4 flagged generic headwinds and IRA pricing. Tariffs compound $9B Sidera charge impacts.
| Metric | FY2025 Value |
|---|---|
| Revenue | $65.0B (+1% YoY) |
| Gross Margin | 81.5% |
| EBITDA Margin | 39.0% |
| Net Income | $18.3B |
| Market Cap | $300B |
| P/E TTM | 16.6 |
| 3M Return | +16.4% |
2026 revenue $65.5-67B. Verdict: Sell—exposed and slowing.
Investment Verdict: Rank the Plays
Top Picks (Buy): 1. Eli Lilly (pure US growth engine), 2. Amgen (biosimilar edge at cheap valuation). Holds: AbbVie, J&J. Avoid (Sell): Pfizer, Merck—highest import risk amid stagnant growth. Allocate to LLY/AMGN for 15-20% upside on tariff implementation.
Risks include delayed tariffs if trade talks falter, IRA price caps eroding all margins, or China retaliation hitting US exports (5% of sector revenue). Monitor Q1 2026 earnings for supply chain updates and US manufacturing capex spikes above $5B.